Wells Fargo
AVDL

Wells Fargo’s Avadel Pharmaceuticals AVDL Stock Holding History

Wells Fargo’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139,943
Closed -$3.02M – 7185
2025
Q4 		$3.02M Buy
139,943
+37,654
+37% +$731K ﹤0.01% 3116
2025
Q3 		$1.56M Buy
102,289
+10,845
+12% +$141K ﹤0.01% 3493
2025
Q2 		$809K Buy
91,444
+7,303
+9% +$64.2K ﹤0.01% 3834
2025
Q1 		$659K Buy
84,141
+974
+1% +$8.16K ﹤0.01% 3901
2024
Q4 		$874K Buy
83,167
+9,719
+13% +$118K ﹤0.01% 3802
2024
Q3 		$963K Sell
73,448
-14,624
-17% -$223K ﹤0.01% 3566
2024
Q2 		$1.24M Buy
88,072
+70,672
+406% +$1.15M ﹤0.01% 3354
2024
Q1 		$294K Sell
17,400
-24,200
-58% -$360K ﹤0.01% 4235
2023
Q4 		$587K Buy
41,600
+24,315
+141% +$286K ﹤0.01% 3758
2023
Q3 		$178K Sell
17,285
-12,815
-43% -$172K ﹤0.01% 4438
2023
Q2 		$496K Buy
30,100
+14,600
+94% +$190K ﹤0.01% 3944
2023
Q1 		$142K Buy
15,500
+7,000
+82% +$57.5K ﹤0.01% 4625
2022
Q4 		$60.9K Sell
8,500
-3,005
-26% -$21.1K ﹤0.01% 4782
2022
Q3 		$58K Sell
11,505
-95
-0.8% -$523 ﹤0.01% 4879
2022
Q2 		$28K Buy
11,600
+1,000
+9% +$4.11K ﹤0.01% 5284
2022
Q1 		$72K Sell
10,600
-81,350
-88% -$559K ﹤0.01% 5471
2021
Q4 		$743K Sell
91,950
-67,050
-42% -$613K ﹤0.01% 4357
2021
Q3 		$1.56M Sell
159,000
-55,950
-26% -$441K ﹤0.01% 3881
2021
Q2 		$1.45M Buy
214,950
+2,950
+1% +$23.4K ﹤0.01% 3959
2021
Q1 		$1.92M Buy
212,000
+187,731
+774% +$1.52M ﹤0.01% 3738
2020
Q4 		$162K Buy
24,269
+15,710
+184% +$98.3K ﹤0.01% 5167
2020
Q3 		$43K Buy
8,559
+1,809
+27% +$13.2K ﹤0.01% 5558
2020
Q2 		$55K Buy
6,750
+4,661
+223% +$41.1K ﹤0.01% 5458
2020
Q1 		$17K Sell
2,089
-1,911
-48% -$14.7K ﹤0.01% 5635
2019
Q4 		$30K Buy
4,000
+2,875
+256% +$15.2K ﹤0.01% 5646
2019
Q3 		$5K Buy
1,125
+125
+13% +$313 ﹤0.01% 6051
2019
Q2 		$3K Hold
1,000
– – ﹤0.01% 6101
2019
Q1 		$1K Sell
1,000
-1
-0.1% -$2 ﹤0.01% 5915
2018
Q4 		$3K Sell
1,001
-1,800
-64% -$6.12K ﹤0.01% 6131
2018
Q3 		$12K Sell
2,801
-731
-21% -$3.95K ﹤0.01% 5943
2018
Q2 		$22K Buy
3,532
+800
+29% +$5.61K ﹤0.01% 5791
2018
Q1 		$20K Buy
2,732
+221
+9% +$1.94K ﹤0.01% 5804
2017
Q4 		$21K Buy
2,511
+1,000
+66% +$9.38K ﹤0.01% 5783
2017
Q3 		$16K Buy
1,511
+511
+51% +$4.88K ﹤0.01% 5764
2017
Q2 		$11K Sell
1,000
-72
-7% -$723 ﹤0.01% 5753
2017
Q1 		$11K Buy
1,072
+72
+7% +$720 ﹤0.01% 5845
2016
Q4 		$10K Sell
1,000
-200
-17% -$2.2K ﹤0.01% 5801
2016
Q3 		$15K Buy
1,200
+164
+16% +$2.14K ﹤0.01% 5672
2016
Q2 		$11K Buy
1,036
+36
+4% +$384 ﹤0.01% 5635
2016
Q1 		$11K Sell
1,000
-6,389
-86% -$63.5K ﹤0.01% 5662
2015
Q4 		$89K Sell
7,389
-5,068
-41% -$79K ﹤0.01% 4993
2015
Q3 		$204K Buy
12,457
+8,022
+181% +$177K ﹤0.01% 4461
2015
Q2 		$93K Buy
4,435
+3,908
+742% +$70.1K ﹤0.01% 5095
2015
Q1 		$9K Sell
527
-14,836
-97% -$232K ﹤0.01% 5656
2014
Q4 		$263K Buy
15,363
+6,359
+71% +$90.8K ﹤0.01% 4292
2014
Q3 		$129K Buy
+9,004
New +$129K ﹤0.01% 4547
2014
Q2 		– Sell
-200
Closed -$3K – 6101
2014
Q1 		$3K Hold
200
– – ﹤0.01% 5621
2013
Q4 		$2K Hold
200
– – ﹤0.01% 5527
2013
Q3 		$1K Hold
200
– – ﹤0.01% 5506
2013
Q2 		$1K Buy
+200
New +$1.03K ﹤0.01% 5444

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Wells Fargo's AVDL Position: Q1 2026 in Review

Wells Fargo sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 139,943 shares — an estimated $3.02M sold.

Wells Fargo first reported a position in AVDL in Q2 2013 and held it in 50 quarters. The position peaked at $3.02M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Wells Fargo reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 139,943 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.02M.
  • Wells Fargo first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Wells Fargo's Avadel Pharmaceuticals position peaked at $3.02M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.